RATIO-TOPISALIC LOTION

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE); SALICYLIC ACID

Sẵn có từ:

TEVA CANADA LIMITED

Mã ATC:

D07XC01

INN (Tên quốc tế):

BETAMETHASONE

Liều dùng:

0.5MG; 20MG

Dạng dược phẩm:

LOTION

Thành phần:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5MG; SALICYLIC ACID 20MG

Tuyến hành chính:

TOPICAL

Các đơn vị trong gói:

30ML/60ML

Loại thuốc theo toa:

Prescription

Khu trị liệu:

ANTI-INFLAMMATORY AGENTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0215695003; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2013-02-22

Đặc tính sản phẩm

_ _
_ratio-TOPISALIC Lotion (Betamethasone Dipropionate and Salicylic
Acid) _
_ _
_Page 1 of 20_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
RATIO-TOPISALIC
Betamethasone Dipropionate (0.5 mg / g as base)
and Salicylic Acid (20 mg / g)
LOTION
TOPICAL CORTICOSTEROID AND KERATOLYTIC
TEVA CANADA LIMITED
Date of Revision:
30 Novopharm Court
April 17, 2020
Toronto, Ontario,
Canada M1B 2K9
www.tevacanada.com
Submission Control No: 235690
_ _
_ratio-TOPISALIC Lotion (Betamethasone Dipropionate and Salicylic
Acid) _
_ _
_Page 2 of 20_
TABLE OF CONTENTS
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
1
INDICATIONS
.................................................................................................................
3
1.1
Pediatrics
...................................................................................................................
3
1.2
Geriatrics
...................................................................................................................
3
2
CONTRAINDICATIONS
................................................................................................
3
3
DOSAGE AND ADMINISTRATION
............................................................................
3
3.1
Dosing Considerations
..............................................................................................
3
3.2
Recommended Dose and Dosage Adjustment
.......................................................... 4
4
MISSED DOSE
.................................................................................................................
4
5
OVERDOSAGE
................................................................................................................
4
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .............. 4
7
WARNINGS AND PRECAUTIONS
..............................................